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Formal Correction: Correction to Funding
Original Article
Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy
Formal Correction: Correction to Funding
The funding information for this paper is missing. It should read:
This work was supported by the Israel Science Foundation (O.M.), the Binational Science Foundation
(O.M.), the AICR (O.M), the ICRF (O.M.), the European Commission (LSHC-CT-2002-518178 and
MRTN-CT-2005 to O.M.), the Israel Ministry of Health (A.P.), the Cooperation Program in Cancer
Research of the Deutsches Krebsforschungszentrum (DKFZ), and Israeli's Ministry of Science and
Technology (MOST) (A.P.).
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